Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 08h10 HE
|
Vaccinex, Inc.
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
01 juin 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h45 HE
|
Vaccinex, Inc.
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25 avr. 2023 08h00 HE
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
12 avr. 2023 08h00 HE
|
Vaccinex, Inc.
GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New...
Vaccinex Announces Private Placement with Commitments of $5.0 Million
03 avr. 2023 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
03 avr. 2023 08h00 HE
|
Vaccinex, Inc.
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for...
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
23 mars 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
21 mars 2023 08h30 HE
|
Vaccinex, Inc.
The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
09 mars 2023 08h00 HE
|
Vaccinex, Inc.
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study...